GSK-J4 targeting KDM6A is an effective therapeutic strategy against craniosynostosis (35), lymphoblastic and myeloid leukemias (37, 38), and breast, ovarian and prostate cancers (39–41). This evidence concerns the gene KDM6A and prostate cancer.